ClinicalTrials.gg
TerminatedNCT07014735Updated Jul 1, 2026

Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM

An interventional study of glucose and moxifloxacin in Diabetes Type 2, Hyperglycaemia (Diabetic) and QT Interval, Variation in, sponsored by Richmond Pharmacology Limited. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Richmond Pharmacology Limited · Not applicable, Interventional, and Basic science

Why this study was terminated
The study is being terminated early on the grounds of futility, as continuation of the study is no longer considered scientifically or operationally justified.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 572 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom — 57 open to participants now, 73 under way, 20 of them phase 3. Diabetes Mellitus, Type 2 · United Kingdom.

Enrollment
463rd of 495
14 · median 207
Started
2023
with 19 others
No phase
155 of 572
25 open now
Registered
510th of 572
by date

Among the 572 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom, this one is the 463rd largest by enrollment of the 495 interventional ones that give a count, is one of 20 that started in 2023, is one of 155 with no phase, and was the 510th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

57 of the 572 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 572 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom, or all of them as a file.
02

Study summary

Diabetes is a significant risk factor for sudden cardiac death, with the QTc interval on electrocardiograms (ECGs) often prolonged in diabetic patients due to factors such as hyperglycaemia and insulin resistance. Drugs like moxifloxacin can further exacerbate this effect, especially in those with diabetes. A previous trial on Type 1 diabetes suggested that hyperglycaemia and moxifloxacin have additive effects, prompting an investigation into whether similar effects occur in Type 2 diabetes (T2DM), particularly in individuals with high insulin resistance. This study aims to evaluate whether moxifloxacin-induced QT-prolongation is amplified by elevated blood glucose levels or insulin deficiency in T2DM patients, considering potential differences between sexes. Blood biomarkers will be analysed to understand the underlying molecular mechanisms. The trial will involve at least 24 male and female participants with insulin-resistant T2DM, aged 18 to 64 years, conducted at Richmond Pharmacology Ltd. Participants will receive treatments with glucose, moxifloxacin, and placebos while closely monitored for side effects during an inpatient stay, followed by outpatient appointments.

Read the detailed description

Diabetes has been established as a key independent risk factor for sudden cardiac death, a common cause of death from cardiovascular disease. The underlying mechanisms for this seem to be complex and multifactorial, but a change in the electrocardiogram (ECG)(which measures the electrical activity of the heart) parameter called QTc interval has been identified as potentially having a significant role. In patients with diabetes, QT interval prolongation is frequently reported. High blood glucose levels (hyperglycaemia) and insulin resistance (the condition where the body does not respond well to insulin) are thought to be important causes. The investigators also know that some drugs e.g., moxifloxacin (a common antibiotic) can prolong the QT interval and this effect can be more pronounced in patients with diabetes.

The investigators have previously conducted a trial on Type 1 diabetes showing that the effects of hyperglycaemia and moxifloxacin were additive. This led to our hypothesis that similar effects might be observed in type 2 diabetes (T2DM), specifically in those with high insulin resistance. Understanding whether the well-established QT-prolongation caused by moxifloxacin is exaggerated by elevated levels of blood glucose alone or by an insulin deficiency is important for evaluating the risk to patients with T2DM and the potential prevention of cardiac complications. The investigators would also like to determine if the effect varies between sexes and gain a comprehensive understanding of the molecular factors driving these differences by analysing blood biomarkers.

This trial will be conducted at Richmond Pharmacology Ltd. involving a minimum of 24 male and female participants with insulin-resistant T2DM, aged 18 to 64 years. The participants will stay in the clinical trials unit, receive treatments with glucose, moxifloxacin, and placebos and will be monitored closely for any side effects. Following the inpatient stay, participants will return to the unit for an outpatient appointment.

03

Conditions studied

  • Diabetes Type 2
  • Hyperglycaemia (Diabetic)
  • QT Interval, Variation in
  • Torsades de Pointes
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients with stable T2DM. Diagnosis of T2DM confirmed by:

    i. Established diagnosis of T2DM documented on medical records and at screening ≥ 48 mmol/mol (6.5%) and ≤ 80 mmol/mol (9.5%). Subjects with HbA1c levels > 80 mmol/mol but ≤ 90 mmol/mol will be considered eligible, subject to approval by an endocrinologist. AND ii. Evidence of high insulin resistance as defined by a HOMA2-IR score within the top quintile of the locally defined cohort, >0.55 (see Appendix 2).

  2. 18-64 years (inclusive) of age (at the date of signing ), with a of 18 to 35 kg/m², inclusive (at screening).
  3. Satisfactory medical assessment with no or relevant abnormalities as determined by medical history, physical examination, vital signs, 12-lead , and clinical laboratory evaluation (haematology, biochemistry, coagulation, and urinalysis) that is reasonably likely to interfere with the participant's ability to complete the study as assessed by the Investigator.
  4. Stable patients with insulin resistant type 2 diabetes treated with one of the following:

    a. Diet and exercise alone, b. Anti-glycaemic monotherapy on metformin, DPP-4i, pioglitazone, an SU or an SGLT-2i.

  5. Able to wash-out anti-glycaemic therapy for ten half-lives prior to dosing or at D-7, whichever is longer, and for the duration of the trial period up to the end of Day 4.
  6. Participants must agree to use the following requirements for the applicable duration:

    1. Female participants of non- (WNCBP): Defined as either (evidence of menopause based on a combination of amenorrhea for at least one year and increased serum follicle-stimulating hormone (FSH) level [> 30 IU/L]), or surgical sterilization (evidence of hysterectomy and/or bilateral oophorectomy). CONTRACEPTION REQUIRED: None
    2. Female participants of childbearing potential (WOCBP) who anticipate being sexually active with a male during the trial (from one complete menstrual cycle prior to the first drug administration until three months after the last drug administration) *: CONTRACEPTION REQUIRED: Highly effective contraception must start one complete menstrual cycle prior to the first day of dosing and continue until three months after drug administration. Highly effective contraception methods for WOCBP include:

      • Combined i.e. (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: **

        • Oral
        • Intravaginal
        • Transdermal
      • Progestogen-only hormonal contraception associated with inhibition of ovulation**

        • oral
        • injectable
        • implantable
      • Intrauterine hormone-releasing system (IUS)**
      • Intrauterine device (IUD)
      • Bilateral tubal occlusion
      • Infertile male partner (e.g., vasectomised, permanently sterile following bilateral orchidectomy, or any other documented cause of infertility)
    3. Female participants of childbearing potential (WOCBP) who agree to remain abstinent for the duration of the trial (from one complete menstrual cycle prior to the first drug administration until three months after the last drug administration): CONTRACEPTION REQUIRED: Abstinence (N.B. sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the trial treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. Calendar, symptothermal and post-ovulation methods of contraception are not considered to be equivalent to abstinence).
    4. Male participants, who agree to remain abstinent for the duration of the trial (from first drug administration until three months after the last drug administration): CONTRACEPTION REQUIRED: Abstinence (N.B. sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the trial treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant). If the situation changes post-dose during the trial, participants must use a condom with or without spermicide.
    5. Male participants, who anticipate being sexually active during the trial period (from first drug administration until three months after the last NIMP administration) with a woman who is either a WOCBP, a woman who is pregnant and/or breast feeding: CONTRACEPTION REQUIRED: From the first day of dosing until the end of the systemic exposure of the trial drug (for this trial this is until the follow-up visit). Acceptable methods are:

      • Male condom with or without spermicide
      • Infertile male (e.g., vasectomised, permanently sterile following bilateral orchidectomy, or any other documented cause of infertility)
  7. Ability to provide written, personally signed, and dated informed consent to participate in the study, in accordance with the ICH Good Clinical Practice (GCP) Guideline E6 (R2) (2016) and applicable regulations, before completing any study-related procedures. An understanding, ability, and willingness to fully comply with study procedures and restrictions.

Exclusion criteria

Exclusion Criteria:

  1. History or clinical evidence of T2DM related secondary complications in particular autonomic neuropathy, cardiac rhythm disturbances, past medical history of syncope and potassium abnormalities.
  2. Currently prescribed or used in the last 12 months any form of insulin therapy, or any long half-life diabetic medication that would not wash-out within 7 days.
  3. History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism, or excretion of the study drug (appendicectomy and herniotomy allowed).
  4. History or clinical evidence of significant microvascular disease including chronic kidney failure, macular degeneration or any other disease attributed to the microvascular system that in the Investigator's opinion may affect the outcome of the study.
  5. Recent hospitalisation due to hypoglycaemia or hyperglycaemia within 28 days before screening.
  6. History or clinical evidence of any disease with a specific to moxifloxacin (, history of tendon disease related to quinolone treatment, and risk of conditions as below).
  7. History of syncope.
  8. Family history of sudden cardiac death.
  9. Clinically significant history or family history of congenital long QT syndrome (e.g., Romano-Ward syndrome, Jervell and Lange-Nielson syndrome) or Brugada syndrome.
  10. History of clinically significant arrhythmias (especially ventricular arrhythmias, atrial fibrillation (AF), recent conversion from AF), or bundle branch block.
  11. History of confirmed ischemic heart disease or current angina (including confirmed previous myocardial infarction, previous PCI, or coronary bypass).
  12. Conditions predisposing the volunteer to electrolyte imbalances other than T2DM (e.g., altered nutritional states, chronic vomiting, anorexia nervosa, bulimia nervosa, and other endocrine disorders including Cushing's' Addison's', or untreated hypo or hyperthyroidism).
  13. abnormalities in the standard 12-lead ECG (at screening, Day -1 or pre-dose of Day 1) and 24-hour 12-lead Holter ECG or an equivalent assessment and/or submaximal exercise test (at screening) which in the opinion of the Investigator will interfere with the ECG analysis.
  14. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes. This includes participants with any of the following (at screening,

    Day-1, or pre-dose on Day 1):

    • Sinus node dysfunction.
    • Clinically significant PR (PQ) interval prolongation.
    • Intermittent second or third degree AV block.
    • Incomplete or complete bundle branch block (QRS >110ms).
    • Sustained cardiac arrhythmia's including (but not limited to) atrial fibrillation or supraventricular tachycardia, any symptomatic arrhythmia except for isolated extra systoles.
    • More than 200 ventricular ectopic beats in 24 hours, or >2% of total beats.
    • Ventricular tachycardia (ventricular tachycardia defined as ≥ 3 successive ventricular ectopic beats at a rate of > 120 bpm).
    • Abnormal T-wave morphology.
    • QT interval corrected using the Fridericia's formula (QTcF) > 450 ms at screening. Participant with borderline deviations (within 10% of upper limit) from these criteria may be included if the deviations do not pose a safety risk, and if agreed between the appointed Cardiologist and the PI.
  15. Has vital signs outside of the following normal range at screening, Day -1, or

    Day 1 pre-dose:

    - Blood pressure (BP):

    Supine BP (after at least 5 minutes of supine rest):

    • Systolic blood pressure: 90 - 140 mmHg.
    • Diastolic blood pressure: 40 - 90 mmHg. - Supine pulse rate after at least 5 minutes of rest: 45 - 90 bpm. At the discretion of the PI, the 24-hour Holter, in addition to the screening vital signs, may be used to assess the resting heart rate.
  16. Signs and/or symptoms of a clinically relevant acute illness in the four-week period prior to screening.
  17. Veins unsuitable for intravenous puncture or cannulation on either arm (e.g., veins that are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture).
  18. Known hypersensitivity to any medicines administered in the trial, including quinolone-class antibiotics.
  19. Unless approved explicitly by the PI, use of any prescription medications within 7 days or 10 half-lives (whichever is longer) prior to Day 1, or any over the counter (OTC) medication (including multivitamin, herbal, or homeopathic preparations, excluding hormonal , hormone replacement therapy, and/or paracetamol- maximum 2g per day) within 7 days prior to Day 1 of the dosing period. Medicines predisposing to lactic acidosis, such as inhaled salbutamol, should not be used for the duration of the dosing period.
  20. Administration of antibiotics 7 days prior to the admission for the study or plan to take antibiotics during the study.
  21. Treatment with an drug within 90 days prior to admission or having participated in more than three investigational drug studies within one year prior to admission.
  22. Unless approved explicitly by the PI, positive test results for alcohol or drugs of abuse at screening and on Day -1.
  23. Female participants who are pregnant (including a positive serum pregnancy test at screening and on Day-1) or breastfeeding.
  24. Presence or history of drug or alcohol abuse in the last 5 years, or inability to refrain from alcohol use from 48 hours before screening, dosing, and each scheduled visit until the end of the study. Alcohol abuse is defined as regular weekly intake of more than 14 units (for both males and females), using the following NHS alcohol tracker http://www.nhs.uk/Tools/Pages/drinkstracker. aspx.
  25. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine containing products in any form (e.g., gum, patch, electronic cigarettes) within 1 month prior to the planned first day of dosing.
  26. Positive test for surface antigen (HBsAg), antibody (HCV Ab), or antibody (HIV Ab) at screening.
  27. Has a legal or mental incapacity or language barriers precluding adequate understanding, co-operation, and compliance with the study requirements at screening.
  28. Any circumstances or conditions, which, in the opinion of the Investigator, may affect full participation in the study or compliance with the protocol.
  29. An inability to follow a standardized diet and meal schedule or inability to fast, as required during the study.
  30. Prior screen failure (where the cause of the screen failure is not deemed to be temporary), participation, or enrolment in this study. Participants who initially failed due to temporary non-medically significant issues are eligible for re-screening once the cause has resolved.
  31. Abstain from blood and plasma donation during the study and up to 3 months after completion of the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
14 participants (actual)

Study arms

  • Placebo comparator
    glucose (controlled hyperglycaemia) and moxifloxacin placebo

    Participants will receive glucose (controlled hyperglycaemia) and moxifloxacin placebo on Day 1. On Days 1 and 3 glucose will be administered intravenously and/or orally with the aim of gradually raising glucose concentration to 25-28 mmol/L over the space of an hour. The 25-28 mmol/L glucose level will be maintained for 1 hour. Intravenous glucose rate will be titrated up and down during the first hour as guided by glucose readings on CGMS/VBG. Glucose will be continuously monitored to guarantee concentration levels are maintained stable. At the 2-hour timepoint (H2), intravenous glucose will be terminated, and blood glucose level will be allowed to start reducing.

    Drug: glucose

  • Experimental
    intravenous glucose in combination with intravenous moxifloxacin

    intravenous glucose in combination with intravenous moxifloxacin (300 mg infused over 45 minutes) on Day 3

    Drug: glucose · Drug: moxifloxacin

Interventions

  • Participants will receive treatments with glucose or matching placebo (please see study design section).

  • Participants will receive moxifloxacin or matching placebo (please see study design section).

06

What researchers measure

Primary outcomes

  1. Clinically significant ECG morphology and interval changes from baseline

    ECG Analysis Mean QT/QTc values will be calculated for each time point (triplicate ECG) for subsequent analyses. Telemetry data gathered during the study may be used in the optional exploratory analysis of drug related QT/QTc interval changes. The primary baseline corrections will be calculated using averaged QTc pre-dose baseline values (three pre-dose time points). This single value will be used to calculate ΔQTc. A supplementary analysis to calculate ΔΔQTc may be performed using pooled placebo data. The effect on QTc will be calculated using concentration-effect analysis based on the placebo-corrected change from average baseline.

    Time frame: Specified timepoints for 4 days and at follow up visit on Day10-D17

  2. Cardiac intervals/subintervals calculated using concentration-effect analysis on Days 1, 2, and 3.

    The primary baseline corrections will be calculated using averaged QTc pre-dose baseline values (three pre-dose time points). This single value will be used to calculate ΔQTc. A supplementary analysis to calculate ΔΔQTc may be performed using pooled placebo data. The effect on QTc will be calculated using concentration-effect analysis based on the placebo-corrected change from average baseline.

    Time frame: Specified timepoints for 3 days

  3. The paired PK of blood glucose and moxifloxacin (Cmax)

    PK parameter: Maximum observed plasma concentration (Cmax) * Glucose * Day 1: Cmax * Day 2: Cmax * Day 3: Cmax * Day 4: Cmax * Moxifloxacin * Day 3: Cmax * Day 4: Cmax

    Time frame: 4 Days

  4. The paired PK of blood glucose and moxifloxacin (Tmax)

    PK parameter: time to reach maximum plasma concentration (Tmax) * Glucose * Day 1: Tmax * Day 2: Tmax * Day 3: Tmax * Day 4: Tmax * Moxifloxacin * Day 3: Tmax * Day 4: Tmax

    Time frame: 4 days

  5. The paired PK of blood glucose and moxifloxacin (AUC)

    PK parameter: Area under the plasma concentration-time curve (AUC). * Glucose * Day 1: AUC * Day 2: AUC * Day 3: AUC * Day 4: AUC * Moxifloxacin * Day 3: AUC * Day 4: AUC

    Time frame: 4 days

  6. Cardiac interval/subinterval parameters

    Cardiac interval/subinterval parameters (QTcF, JTpc, TpTe) prior to glucose administration compared to post-administration

    Time frame: 4 days

Secondary outcomes

  1. Comparison of the PK of blood glucose and moxifloxacin with cardiac interval/subinterval parameters and ECG morphology between sexes on Days 1, 2, 3 and 4

    Comparison between males and females of the paired PK blood glucose and moxifloxacin, and cardiac interval/subinterval parameters (QTcF, JTpc, TpTe) prior to glucose administration compared to post-administration. PK parameters include maximum observed plasma concentration (Cmax), time to reach maximum plasma concentration (tmax), area under the plasma concentration-time curve (AUC). * Glucose * Day 1: Cmax, tmax, AUC * Day 2: Cmax, tmax, AUC * Day 3: Cmax, tmax, AUC * Day 4: Cmax, tmax, AUC * Moxifloxacin * Day 3: Cmax, tmax, AUC * Day 4: Cmax, tmax, AUC * QTcF, JTpc, TpTe o Days 1, 2, and 3.

    Time frame: Specified time points over 4 days

  2. • Concentration effect analysis between male and female volunteers on Days 1, 2, 3 and 4

    Comparison of males vs females of the primary baseline corrections calculated using averaged QTc pre-dose baseline values (three pre-dose time points). This single value will be used to calculate ΔQTc. A supplementary analysis to calculate ΔΔQTc may be performed using pooled placebo data. The effect on QTc will be calculated using concentration-effect analysis based on the placebo-corrected change from average baseline.

    Time frame: specified timepoints over 4 days

  3. The incidence of treatment-emergent adverse events (TEAEs)

    Proportion of participants with clinically significant changes in laboratory safety tests (haematology, chemistry, coagulation and urinalysis), proportion of participants with morphological and/or rhythm abnormalities on ECG, proportion of participants with clinically significant changes in ECG time intervals (PR, QRS, QT and QTc intervals) and proportion of participants with clinically significant changes in vital signs (systolic blood pressure, diastolic blood pressure, pulse rate, respiratory rate and tympanic temperature).

    Time frame: From screening to follow up approximately 75 days

Other outcomes

  1. To gain a comprehensive understanding of the molecular factors driving differences between male and female participants, by analysing a set of relevant biomarkers: insulin, C-peptide and glucagon.

    Change from baseline for individual biomarkers over time, correlated with changes in blood glucose and QTc interval parameters, ECG morphology and concentration effect analysis.

    Time frame: 3 days

07

Study locations

1 site
  • Richmond Pharmacology Ltd.
    London, SE1 1YR, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in May 2026, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2023
First posted
Jun 11, 2025
StartActual
Apr 13, 2023
Primary completionActual
May 31, 2026
CompletionActual
May 31, 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07014735
Lead sponsor
Richmond Pharmacology Limited
Collaborators
Richmond Research Institute
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Apr 13, 2023
Primary completion
May 31, 2026
Completion
May 31, 2026
Last update
Jul 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion